Table of Contents Author Guidelines Submit a Manuscript
Behavioural Neurology
Volume 13, Issue 3-4, Pages 117-121

Pergolide Mesilate May Improve Fatigue in Patients with Parkinson’s Disease

Kazuo Abe, Mayako Takanashi, Takehiko Yanagihara, and Sabro Sakoda

Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan

Received 28 September 2002; Accepted 28 September 2002

Copyright © 2002 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objectives: Fatigue is a complaint frequently encountered among patients with Parkinson’s disease (PD). Considering the possible relationship between fatigue and dopaminergic dysfuncion, we investigated the effect of pergolide mesilate (a D2 and D1 dopamine receptor agonist) and bromocriptine (a D2 selective dopamine receptor) in patients with PD.

Methods: We evaluated 41 patients with PD and controls. We assessed the degree of fatigue by using a fatigue scale. The severity of PD was evaluated by the Hoehn and Yahr Scale and the unified Parkinson’s disease rating scale (UPDRS).

Results: After five weeks from prescription, patients taking pergolide mesilate showed significant improvement in the fatigue scale (from 5.1 ± 0.7 to 4.4 ± 0.55, p < 0.05, ) but patients taking bromocriptine did not (from 4.8 ± 0.9 to 4.7 ± 0.8).

Conclusions: Our study suggested the possibility of functional correlation between fatigue and D1 receptor in patients with PD.